RxDoctor Payments Data

Keri Ingrassia Squiers, DO

Internal Medicine · Hackettstown, NJNPI 1467465203

Payments from drug & device makers

$2,564in general payments, 2019–2025

Across 187 payments — averaging $13.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$457
  • Novo Nordisk$441
  • GSK$296
  • Pfizer$186
  • AbbVie$164
  • Amgen$133
  • plus $888 from 19 others

What the payments were for

  • Food & beverage$2,552100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,564 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$405,371
Medicare patients
615
Services billed
4,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$102,042
OzempicSemaglutide80$99,330
TrulicityDulaglutide65$95,577
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$36,534
JardianceEmpagliflozin35$33,073
FarxigaDapagliflozin Propanediol28$24,149
MyrbetriqMirabegron51$18,926
XareltoRivaroxaban22$18,095
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,726
JanuviaSitagliptin Phosphate36$14,582
ArexvyRsvpref3 Antigen/As01e/Pf38$11,497
Lagevrio (Eua)Molnupiravir13$7,600
Tresiba Flextouch U-100Insulin Degludec13$5,932
Breo ElliptaFluticasone/Vilanterol12$5,069
Levothyroxine Sodium412$4,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$102,042214 claims
Novo NordiskOzempic$441$99,33080 claims
Lilly USA, LLCTrulicity$126$95,57765 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta, Shingrix$296$74,325131 claims
Boehringer IngelheimJardiance$95$33,07335 claims
AstraZenecaFarxiga, Symbicort$457$28,49039 claims
MerckJanuvia, Lagevrio (Eua)$114$22,18249 claims
Astellas Pharma US IncMyrbetriq$70$18,92651 claims
Johnson & JohnsonXarelto$26$18,09522 claims
AbbVieCombigan, Synthroid$164$3,66829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hackettstown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →